Qing Zhu, Jianxi Tang, Hyewon Youn, Ossama Tawfik, Paul F. Terranova, Jie
Du, Patrick Raynal, J. Brantley Thrasher, and Benyi Li. Phosphoinositide
3-OH kinase p110b is essential for androgen receptor transactivation and tumor
growth in prostate cancer. Oncogene, in press,
April 2008.
Aijing Sun, Jianxi Tang, Yan Hong, Jiawu Song, Paul F. Terranova, J. Brantley
Thrasher, Stan Svojanovsky, Hong-gang Wang and Benyi Li.
Androgen Receptor-dependent Regulation of Bcl-xL Expression: Implication
in Prostate Cancer Progression. The Prostate, 2008,
68(4):453-461.
Shen FY, Benyi Li. [Anti-apoptotic effect of the androgen
receptor in human prostate cancer]. Zhonghua Nan Ke Xue. 2007
Dec;13(12):1121-4.
Ilanchezhian Shanmugam, Guangming Cheng, Paul F. Terranova, J. Brantley
Thrasher, Christie P. Thomas, and Benyi Li. Serum/Glucocorticoid-induced
Protein Kinase-1 Facilitates Androgen Receptor-dependent Cell Survival. Cell
Death and Differentiation, 2007, 14(2):2085-2094.
Aijing Sun, Ilanchezian Shanmugam, Hyewon Youn, Jiawu Song, Paul F. Terranova,
J. Brantley Thrasher, and Benyi Li. Lithium suppress cell
proliferation and E2F-mediated gene expression by disrupting E2F-DNA interaction
in prostate cancer cells. The Prostate, 2007, 67(9):976-988.
Benyi Li, Aijing Sun, Hyewon Youn, Yan Hong, Paul F. Terranova,
J. Brantley Thrasher, and Pingyi Xu. Conditional Akt activation promotes
androgen-independent progression of prostate cancer. Carcinogenesis,
2007, 28(3):572-83.
Benyi Li, Liao XB, Fujito A, Thrasher JB, Shen F, Xu PY.
Dual androgen-response elements mediate androgen regulation of mmp-2 gene
expression in prostate cancer cells. Asian Journal of Andrology,
2007, 9(1):41-50.
Sun A, Tawfik O, Geyrad B, Thrasher JB, Hoesije, S, Li C and Benyi
Li. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is
associated with tumor development and increased invasiveness in prostate
cancers. The Prostate, 2007; 67(2):203-13.
Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P,
Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer
cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther.
2005; 4(9):1311-9.
Liao X, Tang S, Griebling T, Thrasher JB, and Benyi Li.
siRNA-mediated androgen receptor silencing leads to apoptotic cell death
in prostate cancer. Mol
Cancer Therapeutics, 2005, 4(4):505-15.
Liao X, Thrasher JB, Holzbeierlien J, Scott S, and Benyi Li.
GSK-3b activity is required for androgen-stimulated gene expression. Endocrinology,
145:2941-2949, 2004. (As corresponding author).
Liao X, Zhang L, Du J, Thrasher JB and Benyi Li. GSK-3b
suppression eliminates TRAIL resistance in prostate cancer. Mol Cancer Therapeutics,
2003; 2:1215-1222.
Liao X, Thrasher JB, Pelling J, Sang QX, Holzbeierlien J and Benyi
Li. Androgen stimulates MMP2 expression in human prostate cancer. Endocrinology 2003;
144:1656-1663.
Meeting Abstracts
Li B and Liao X. Androgen induction of MMP-2 expression in prostate cancer.
September 2002; American Association for Cancer Research (AACR)
Specific Conference on MMPs, Hilton Head Island, SC.
Li B and Thrasher JB. GSK‑3b activity
is required for androgen receptor transactivation in prostate cancer.
April 2003. The American Urological Association (AUA), Annual Meeting, Chicago,
IL.
Liao X and Li B. siRNA-mediated AR silencing leads to apoptotic cell death in
prostate cancer cells.
March 2004, the American Association for Cancer Research (AACR) annual meeting.
Orlando, FL
Li B and Tang S. 14-3-3 proteins in prostate cancer.
Feb 2004, The first Gordon conference on [the Biology of 14-3-3]. Ventura,
CA.
Li B and Liao X. Bcl-xL as a downstream effecter in AR-mediated survival.
October 2004, The 11th Annual Scientific Retreat, Prostate Cancer Foundation,
Reno, NV
Li B and Liao X. AR-mediated regulation of Bcl-xL expression in prostate cancer.
Feb 2005, The Keystone Symposium of Hormonal Regulation of Tumorigenesis.
Monterey, CA.
Li B and Thrasher JB. Androgen Receptor-mediated Bcl-xL expression in prostate cancer.
May 2005, The American Urological Association (AUA) annual meeting, San Antonio,
TX.
McIntosh J, Thrasher JB and Li B. Galpha12 is required for androgen-induced gene expression in
prostate cancer.
May 2006, the American Urological Association (AUA) annual Meeting, Atlanta,
GA.
Youn H, Thrasher JB and Li B. G-proteins in modulation of AR transactivation.
October 2006, The 85th Annual Meeting, South Central Section,
American Urological Association (AUA), Santa Fe, NM
Li B and Shanmugam I. SGK-1 facilitates AR-dependent survival in prostate cancer.
November 2006, American Association for Cancer Research (AACR)
Special Conference on “Inovations in Prosatte Cancer Research”,
San Francisco, CA
Li B and Tang S. Androgen Receptor siRNA eliminates prostate cancer in vivo
Mar 2007, “Molecular Targets for Cancer (X3)”, Keystone Symposium
Series,
Whistler Resort, Whistler, British Columbia, Canada
Li B and Sun A. Systemic delivery of AAV-based AR siRNA constructs eradicates
prostate cancer in nude mice.
September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
Li B and Tang S. Conditional Akt activation promotes androgen-independent progression
of prostate cancer.
September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
Tang J, Hong Y, Thrasher JB and Li B. AAV-based AR siRNA constructs eradicate prostate cancer in nude
mice.
April 2008, American Association for Cancer Research (AACR) Annual Meeting,
San Diego, CA
Yang J, Tang J and Li B. GSK-3 modulates Autophagy after growth factor depletion.
April 2008, American Association for Cancer Research (AACR) Annual Meeting,
San Diego, CA
Davis J, Thrasher JB and Li B. PI3K p110b is
required for androgen receptor signaling and tumor progression in prostate
cancers.
May 2008, American Urological Association (AUA) Annual Meeting, Orlando,
FL
©
The University of Kansas Medical Center